Premium
Thrombocytopenia after transcatheter aortic valve replacement: What is really going on?
Author(s) -
Block Peter C.,
Lisko John C.
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28353
Subject(s) - medicine , cardiology , valve replacement , aortic valve replacement , aortic valve , stenosis
Key Points In a multivariate model, the drop‐in platelet count (DPC) was significantly higher in patients treated with a balloon expandable valve (BEV) than a self‐expandable valve (SEV) (36.3% ± 15.1% vs. 27.7% ± 14.4%, p < .001). In a univariate model, a higher DPC post‐transcatheter aortic valve replacement was observed in patients requiring alternate access and lower contrast volume. The platelet count nadir was nearly a day later in patients implanted with a BEV compared with an SEV. At 30 days, there was a higher rate of adverse events and mortality in patients with a high DPC. At 1 year, there was no significant difference in mortality rates between the high DPC group and the low DPC group.